Helix BioPharma Corp. (HBP.TO)

Toronto - Toronto Real Time Price. Currency in CAD

Add to watchlist

0.5800+0.0100 (+1.75%)

At close: 1:09PM EDT

Advertisement

Full screen

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Neutralpattern detected

View all chart patterns

Performance Outlook

Previous Close	0.5700
Open	0.5700
Bid	0.5800 x 0
Ask	0.6000 x 0
Day's Range	0.5700 - 0.5800
52 Week Range	0.2500 - 1.1600
Volume	3,366
Avg. Volume	11,128

Market Cap	81.857M
Beta (5Y Monthly)	-0.09
PE Ratio (TTM)	N/A
EPS (TTM)	-0.0540
Earnings Date	Jun 14, 2021
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	2.10

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

N/A

Subscribe to Yahoo Finance Plus to view Fair Value for HBP.TO

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

News

Press Releases

ACCESSWIRE
Helix BioPharma Corp. Announces Appointment of Interim Chief Executive Officer
RICHMOND HILL, ON / ACCESSWIRE / September 20, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the Company's Chairman of the Board, Prof.
ACCESSWIRE
Helix BioPharma Corp. Announces Appointment of New Director
RICHMOND HILL, ON / ACCESSWIRE / August 19, 2021 / Helix BioPharma Corp. (TSX:HBP) ('Helix' or the 'Company'), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that Dr.
ACCESSWIRE
Helix BioPharma Corp. Announces Changes to the Company's Board of Directors and Management
RICHMOND HILL, ON / ACCESSWIRE / June 30, 2021 / Helix BioPharma Corp. (TSX:HBP) ('Helix' or the 'Company'), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that Heman Chao has notified the Board of Directors of the Company of his intention to step down from the position of Chief Executive Officer ("CEO"), Chief Scientific Officer ("CSO") and member of the Board, effective September 1, 2021.